Medivir names new CEO (again)

Oct. 25, 2021

Medivir announced that its Board of Directors has appointed Jens Lindberg as CEO of the company — the fourth person to fill the position for the Stockholm-based cancer drug developer in the last two years.

Lindberg is a 25-year AstraZeneca vet, last serving as VP of oncology for the drugmaker before taking on a new role at Sedana Medical in early 2020. There, Lindberg was responsible for building up the Sweden-based medtech's pharmaceutical capabilities and readiness for its first commercial launch in early 2022.

Jens Lindberg will assume the position as CEO within six months when he will replace Magnus Christensen, currently serving as interim CEO. Christensen, Medivir’s CFO, took on the interim CEO position back in April, filling in for Yilmaz Mahshid, who left after only 6 months on the job. Mahshid had taken the reigns as CEO in September 2020, replacing Uli Hacksell, who had been CEO since October 2018.

Now, Lindberg's expertise in oncology will come in handy, as he focuses on expanding the development program for Medivir's lead product candidate for liver cancer, and maximizing the value of other programs through collaborations and partnerships.

>>>>Read more about the Swedish pharma industry